🚨 Highlights from #AVITHRAPID at #INFACT2025 (Naples, April 3–5)! Harnessing Computational Power – Presented by Carmine Talarico 💻 AVITHRAPID’s in silico pipeline for antiviral targets 🧬 Applied to Dengue virus 🔍 Public workflows, docking & MD-ready models

AVITHRAPID was showcased at #AREVIR2025 in Cologne! Francesca Incardona (EuResist) presented our mission to a hybrid audience of 120+ experts in infectious diseases, virology & AI. Thanks to the organizers for the spotlight! 🌐 avithrapid.eu #HorizonEU #OneHealth

🔬 AVITHRAPID's Latest Discovery: Halicin Targets SARS-CoV-2 3CLpro. Our new study reveals that halicin binds to both Cys145 and Cys44 in 3CLpro, disrupting its function and stability. This dual targeting offers a promising avenue for broad-spectrum antiviral development .

The next pandemic won’t be a test of science. It’ll be a test of coordination. We don’t lack solutions—we lack aligned priorities, fast adaptation, and collective courage. 🧠 Think less tech. More systems thinking. #GlobalHealth #PandemicPrep #HealthSecurity #AVITHRAPID

Meet Paulo Silva, R&D Specialist at IT4Innovations key partner in #AVITHRAPID. With HPC expertise, Paulo drives the in-silico engines accelerating antiviral discovery. 📷 Watch the video & see how supercomputing helps fight pandemics! #HPC #PandemicPreparedness

Market gaps in broad-spectrum antivirals are clear: limited discovery platforms, resistance concerns, clinical trial barriers, and access issues. It’s time to bridge these gaps and innovate to protect global health. Subscribe to our newsletter: avithrapid.eu

Our consortium partners are meeting next week in Berlin for an exciting session to exchange ideas, review progress, and plan upcoming work. Are you part of a team focused on antiviral development? Reach out to explore future collaborations with us! #AVITHRAPID #Collaboration

Neglected tropical diseases (NTDs) affect over 1.5 billion people worldwide, yet treatment options remain limited. Broad-spectrum antivirals offer a promising solution. Let’s push for innovation and progress. Stay informed on the latest updates—subscribe to our newsletter at

🧪 Last 16-17 June, the #AVITHRAPID team met in Berlin to plan next steps in antiviral preparedness! Great science, strong collaboration — and a few laughs too 😄 📸 Highlights below! #HorizonEU #DrugRepurposing #PandemicPreparedness

What’s next for #AVITHRAPID? After our meeting in Berlin, we’re moving into a key phase: advancing known antivirals and exploring novel broad-spectrum candidates. A dual strategy for a faster, smarter response to future threats. #HorizonEurope #OneHealth. #EUresearch #Antivirals

🤝 AVITHRAPID & @AREASciencePark signed a Memorandum of Understanding on July 15th! Together, we’ll: 🔹 Build a 100-day antiviral response framework 🔹 Co-develop EU + global proposals 🔹 Train, engage & expand impact beyond the project #AVITHRAPID #HealthSecurity

#WorldHepatitisDay The HCV story taught us that targeted antivirals work. AVITHRAPID is building on that lesson to develop next-gen, broad-spectrum drugs for emerging threats. #AVITHRAPID #ScienceTwitter

🌐 Meet the #AVITHRAPID consortium: ✅ 18 partners 📍 8 countries 🧠 1 shared mission - accelerate antiviral discovery in Europe. #EUHealth #ScienceTwitter

#WorldBreastfeedingWeek Zika and other viruses can impact mothers and infants. #AVITHRAPID is committed to inclusive, responsible science - because preparedness must protect everyone. #HealthEquity #PandemicScience

What sets broad-spectrum antivirals (BSAs) apart? - Active against multiple viruses - Target shared viral enzymes or host cell pathways - Useful in early outbreak response & pandemics ⚠️ But: - Potential toxicity - Risk of resistance - Often less specific than tailored antivirals

📬 Want updates on antiviral R&D, EU science policy & project milestones? Subscribe to the #AVITHRAPID newsletter for: 🔬 Research highlights 📅 Events & seminars 🌍 Stakeholder news 👉 Sign up now #ScienceTwitter #PandemicPreparedness

🚨 New announcement is out: #AVITHRAPID & Area Science Park join forces for innovation in antiviral R&D. The new MoU advances the 100-Day Response Framework & creates new EU-level pathways for pandemic preparedness. Read more 👉 avithrapid.eu/avithrapid-and… #HealthSecurity

🧪 Vaccines prevent. Antivirals treat. Both are vital — but which will shape the future of infectious disease? 🦠 - Vaccines - Antivirals - Both equally - Not sure 👉 Vote in the poll and share your thoughts in the comments! Your perspective matters for the future of global

✅ Thanks for voting in our poll! The takeaway? 👉 Vaccines = prevention 👉 Antivirals = treatment They are not competitors — they work together to build a stronger response to infectious diseases. At #AVITHRAPID, we focus on advancing antivirals to complement vaccines and

🤖 How will AI transform drug discovery? - Faster development - Personalized treatments - Lower costs - Not sure yet Vote & share your view! #AVITHRAPID #AI #Biotech